The health insurance authorities have once again started analysis on the fiscal impact of reimbursing diabetes combination drugs.

In the latest financial impact analysis, a red light was turned on in reimbursing the combined use of diabetes drugs as the reimbursement amount exceeded the government’s range of expectations. Whether the newly submitted price cut proposals will satisfy the government's expectations and finally allow reimbursement to be made for diabetes combinations is gaining attention.

According to industry sources on the 6th, the Ministry of Health and Welfare collected the voluntary price cut rates submitted by 11 pharmaceutical companies related to the reimbursement o